Mar 17, 2026 (MarketLine via COMTEX) --
Purple Biotech said it received confirmation from Nasdaq's Listing Qualifications Department that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
To regain compliance with Nasdaq Listing Rule 5550(a)(2), the Company was required to maintain a minimum closing bid price for the American Depositary Shares (the "ADSs") of $1.00 per share or more for at least 10 consecutive business days, which was achieved on March 13, 2026.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
COMTEX_478962034/2227/2026-05-11T22:18:45
Copyright (C) 2026 Datamonitor. All rights reserved
